Laurence G Trahair1, Michael Horowitz, Trygve Hausken, Christine Feinle-Bisset, Christopher K Rayner, Karen L Jones. 1. Discipline of Medicine (L.G.T., M.H., C.F.-B., C.K.R., K.L.J.), The University of Adelaide, Adelaide 5005, Australia; National Health and Medical Research Council Centre of Research Excellence in Translating Nutritional Science to Good Health (L.G.T., M.H., C.F.-B., C.K.R., K.L.J.), The University of Adelaide, Adelaide 5005, Australia; and Section for Gastroenterology (T.H.), Department of Clinical Medicine, University of Bergen, N-5020 Bergen, Norway.
Abstract
CONTEXT: Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR). OBJECTIVE: To determine whether exogenous GLP-1 modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR, and splanchnic blood flow in healthy older subjects. DESIGN: A double-blind randomized trial was conducted. SETTING:Community-dwelling residents attended a clinical research laboratory. PATIENTS: Ten healthy "older" subjects (9 male, 1 female; age 73.2 ± 1.5 y) were studied. INTERVENTIONS: Intravenous infusion of GLP-1 (0.9 pmol/kg/min), or saline (0.9%) for 90 min (t = -30-60 min). Between t = 0-60 min, ID glucose was infused at 3 kcal/min. MAIN OUTCOME MEASURES: BP, HR, superior mesenteric artery (SMA) flow, blood glucose, and serum insulin were measured. RESULTS: During the fasting period (t = -30-0 min), GLP-1 had no effect on BP or HR. In response to ID glucose (t = 0-60 min), systolic BP decreased (P < .001), and both HR (P < .001) and SMA flow (P < .05) increased, on both days. GLP-1 attenuated the maximum decrease in systolic BP (P < .05), tended to increase HR (P = .09), and increased SMA flow (P < .01). GLP-1 diminished the glycemic response (P < .05). CONCLUSIONS: In healthy older subjects, acute administration of GLP-1 attenuates the hypotensive response to ID glucose, and potentiates the increase in SMA flow.
RCT Entities:
CONTEXT: Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR). OBJECTIVE: To determine whether exogenous GLP-1 modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR, and splanchnic blood flow in healthy older subjects. DESIGN: A double-blind randomized trial was conducted. SETTING: Community-dwelling residents attended a clinical research laboratory. PATIENTS: Ten healthy "older" subjects (9 male, 1 female; age 73.2 ± 1.5 y) were studied. INTERVENTIONS: Intravenous infusion of GLP-1 (0.9 pmol/kg/min), or saline (0.9%) for 90 min (t = -30-60 min). Between t = 0-60 min, ID glucose was infused at 3 kcal/min. MAIN OUTCOME MEASURES: BP, HR, superior mesenteric artery (SMA) flow, blood glucose, and serum insulin were measured. RESULTS: During the fasting period (t = -30-0 min), GLP-1 had no effect on BP or HR. In response to ID glucose (t = 0-60 min), systolic BP decreased (P < .001), and both HR (P < .001) and SMA flow (P < .05) increased, on both days. GLP-1 attenuated the maximum decrease in systolic BP (P < .05), tended to increase HR (P = .09), and increased SMA flow (P < .01). GLP-1 diminished the glycemic response (P < .05). CONCLUSIONS: In healthy older subjects, acute administration of GLP-1 attenuates the hypotensive response to ID glucose, and potentiates the increase in SMA flow.
Authors: Laurence G Trahair; Michael Horowitz; Julie E Stevens; Christine Feinle-Bisset; Scott Standfield; Diana Piscitelli; Christopher K Rayner; Adam M Deane; Karen L Jones Journal: Diabetologia Date: 2015-06-06 Impact factor: 10.122
Authors: Nam Q Nguyen; Tamara L Debreceni; Carly M Burgstad; Melissa Neo; Max Bellon; Judith M Wishart; Scott Standfield; Dylan Bartholomeusz; Chris K Rayner; Gary Wittert; Michael Horowitz Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: Mark M Smits; Marcel H A Muskiet; Lennart Tonneijck; Trynke Hoekstra; Mark H H Kramer; Michaela Diamant; Daniël H van Raalte Journal: Br J Clin Pharmacol Date: 2016-01-25 Impact factor: 4.335
Authors: Jukka Koffert; Henri Honka; Jarmo Teuho; Saila Kauhanen; Saija Hurme; Riitta Parkkola; Vesa Oikonen; Andrea Mari; Andreas Lindqvist; Nils Wierup; Leif Groop; Pirjo Nuutila Journal: Endocr Connect Date: 2017-03-03 Impact factor: 3.335